CRP and type 2 diabetes mellitus: Salsalate, a prodrug of salicylate that inhibits the NF-κB pathway, has shown promising effects on lowering glucose levels, glycated hemoglobin levels, and serum C-reactive protein (CRP) in patients with T2DM, although slight increases in low-density lipoprotein (LDL), cholesterol, and urinary albumin levels were also observed17,18.